Mezigdomide
- Generic Name
- Mezigdomide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H30FN5O4
- CAS Number
- 2259648-80-9
- Unique Ingredient Identifier
- LA88IH4O02
- Background
Mezigdomide is under investigation in clinical trial NCT05372354 (A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Phase 3
Recruiting
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 525
- Registration Number
- NCT05552976
- Locations
- 🇺🇸
Emory University School of Medicine- Grady Campus, Atlanta, Georgia, United States
🇩🇪GEFOS Gesellschaft f. onkologische Studien, Dortmund, Nordrhein-Westfalen, Germany
🇯🇵Nihon University Itabashi Hospital, Itabashiku, Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath